Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)
(2016)
Journal Article
Bedaquiline (a.k.a., Sirturo) is an anti‐microbial agent, which is approved by the FDA for the treatment of multi‐drug resistant pulmonary tuberculosis (TB). Bedaquiline is a first‐in‐class diaryl‐quinoline compound, that mechanistically inhibits the... Read More about Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs).